Christian Angermayer, founder and chairman of Atai Life Sciences ATAI, told Twitter that he bought 1 million shares of his company.
“Many #biotech stocks are cheap at the moment. In my opinion, Atai Life Sciences AG stands out though for two reasons: the size of the market (unfortunately) & the fact that the compounds historically selected by atai have prior human or anecdotal evidence. Hence I have increased my stake via a capped call of 1m shares as filing today,” he explained on LinkedIn.
At the current stock price, the transaction by Angermayer is around $4 million, a show of trust in the potential of his company. Through his investment firm, Apeiron Investment Group, Angermayer is set on standing by what he wrote last December and “put his money where his mouth is.”
These last few months have been kind to Atai, upping its Compass Pathways CMPS stake from 19.4 to 20.8 percent, and with a positive financial results report for 2021.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!